Monday, 28 Sep 2020

Janssen: Long-term Trial Shows TREMFYA As Efficacious Therapy In Plaque Psoriasis

Trump Tweet Mocking ‘Unpresidential’ Obama Walk Resurfaces After Ramp Incident

President Donald Trump fired off a tweet over the weekend to defend his unusually slow and tentative walk down a ramp after speaking at West Point on Saturday.  

But a few years ago, he had a very different idea about how a president should walk. 

Trump didn’t like how then-President Barack Obama walked down the stairs of Air Force One, declaring it “inelegant and unpresidential”:

On Saturday, Trump raised alarms on social media after he appeared to struggle to lift a glass of water during his speech at West Point, then had difficulty walking down the ramp. 

The criticism seemed to strike home. He responded on Twitter that the ramp was “very long & steep” and also “very slippery.” However, the weather was clear and the ramp was dry and lined with no-slip strips.  

His behavior caused #TrumpIsNotWell to trend on Twitter. 

BBLS queue dismays small firms while directors taking dividends still seek support

Many desperate traders however looking to the Bounce Back Loan Scheme (BBLS) to rescue them say are caught up in long approvals queues with issuing banks.

“The help needs to be speeded up or it will be too late,” they tell us.

++ If you’ve been affected by this issue or feel you’ve been a victim of injustice, please contact consumer and small business champion Maisha Frost on [email protected] ++;

Commerzbank to cut jobs, close branches; Cerberus is "rude" – supervisory board member

FRANKFURT, June 15 (Reuters) – Commerzbank will announce “considerably” more branch closures and job cuts when lays out its strategy review, a member of the bank’s supervisory board said on Monday as he criticized a public campaign for change by a top investor, Cerberus.

“Cerberus’ approach is rude and inappropriate,” Commerzbank supervisory board member Stefan Wittmann told Reuters. (Reporting by Tom Sims Editing by Riham Alkousaa)

SThree Plc H1 Group Net Fees Down 7% – Quick Facts

SThree Plc (STHR.L) reported that its first half Group net fees were down 7% to 151.2 million pounds, with second quarter down 12%, impacted by Covid-19 Contract showing resilience with net fees down 5%. The Group said the robust performance in its first quarter was outweighed by the impact of the COVID-19 pandemic in its second quarter across all of its territories and sectors.

SThree said it remains in a strong financial position, with net cash at 31 May 2020 of 31 million pounds. The Group has a 50 million pounds revolving credit facility with HSBC and Citibank, which is committed to 2023.

Ex-Actor Hopes to Unseat Tokyo’s Governor on Platform for Canceling Olympics

A former actor said he would run in next month’s election for Tokyo governor, seeking to upend the incumbent front-runner for the job with a platform based on canceling next year’s summer Olympics.

Taro Yamamoto, whose upstart party won two seats in last year’s upper house election, told a news conference Monday that the money and labor being devoted to the global sports spectacle could be better spent elsewhere. He is seeking to unseat Yuriko Koike, whose popularity has been bolstered by her handling of the virus crisis.

Abe Rival Says Japan Sales Tax Hike ‘Crazy,’ Wants It Abolished

Koike and other Japanese officials have denied they are considering canceling the Tokyo games, which have been postponed by a year to 2021 because of the pandemic. They are already set to be scaled back to save money.

Lawyer and anti-poverty campaigner Kenji Utsunomiya and Kumamoto prefecture’s deputy governor, Taisuke Ono, have also announced they will run in the election, but Koike has a clear lead on any rival. A poll published in early June found her approval rating had leaped by 20 percentage points in the past two months to 70%.

Janssen: Long-term Trial Shows TREMFYA As Efficacious Therapy In Plaque Psoriasis

Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) announced Monday new long-term plaque psoriasis data for TREMFYA (guselkumab).

The company noted that the first-in-class treatment showed consistent, high levels of skin clearance through four years in adult patients with moderate to severe plaque psoriasis.

In the open-label extension of VOYAGE 2, at four years, 80 percent of patients who were treated with guselkumab 100 mg every 8 weeks, achieved at least 90 percent improvement in the Psoriasis Area and Severity Index or PASI 90 score.

According to the company, Guselkumab is the first monoclonal antibody that selectively binds to the p19 subunit of IL-23, and inhibits its interaction with the IL-23 receptor, to have been approved by the European Commission.

Kristian Reichi, lead investigator of the VOYAGE 2 study, said, “Results from the VOYAGE 2 study demonstrate guselkumab as an efficacious therapy through four years, providing patients who may be experiencing chronic psoriatic symptoms with a long-term treatment option.”

Separately, data from the randomised, placebo-controlled, head-to-head, Phase 3 VOYAGE 1 trial comparing patient-reported outcomes between those being treated with guselkumab and those being treated with adalimumab are also being shared online as a poster.

The new analysis show a higher proportion of patients treated with guselkumab reported symptom-free and sign-free status through 48 weeks versus adalimumab.

Related Posts